Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > 52 week low

<< Previous

Bullboard Posts

Next >>

Comment by baggerx99on Jul 17, 2021 9:13pm

119 Views

Post# 33565871

RE:RE:RE:RE:52 week low

Dan is accountable to the Board of ATE, they must be satisfied with his actions...maybe start with over throwing the board.....really??

Layth1990 wrote:
Board Independence
Pursuant to NI 58-101, a director is independent if he or she has no direct or indirect material relationship with the issuer that could, in the view of the issuer’s board of directors, be reasonably expected to interfere with the exercise of a member’s independent judgment. Certain directors are deemed to have a material relationship with the issuer by virtue of their position or relationship with the Corporation.

The Board is comprised of Walt Macnee (Chair), Roderick Flower, Robert Hoffman, Amal Khouri, Dan Legault, Jennifer McNealey, John Wallace and Yung Wu. The independent directors are Walt Macnee, Roderick Flower, Robert Hoffman, Amal Khouri, Jennifer McNealey and Yung Wu. Dan Legault and John Wallace are not considered independent directors as they both hold positions as executive officers of the Corporation.

The members of the Board have been elected by the shareholders to oversee the management of the business and affairs of the Corporation and are mandated to act with a view to the best interests of the Corporation as a whole at all times. The Board reviews its procedures on an ongoing basis to ensure that it can function independently of management. Currently, the Board is satisfied that it discharges its responsibility for independent oversight of management given that the majority of the Board is independent, the requirement for directors to disclose any conflicts of interest, and the ability of the independent directors to hold in camera meetings and to form ad hoc independent board committees as deemed necessary.I have not voted before but i will definitly do it in augurst. I know 40k shares do not have a good voting power but it is significant. Since last year he is ruining the company. We got into ph3 and we got a good deal. His financing strategy after nuance deal is sh*t play of the century. He sold tons of shares because he knows PH3 will get postponed. Not to mention he said there will be no dilution year ago and he diluted us twice. Where is nasdaq and why reverse split? He is the worst ceo when it comes to schedule, was there anything on time ? No

I am pretty sure if dan is out, the company will do great. As long as he is the ceo it is a sinking ship because he ia greedy and knows nothing about investing. What type of ceo sells shares while the stock is sinking? He will probably buy when stock hits 2.5 and magically he will have money.